Ron Bentsur
Chairman & CEO at Nuvectis Pharma Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Nuvectis Pharma Inc., 3 years.
Nuvectis Pharma Inc.
Director · Chairman & CEO
Beyond Air Inc.
Director
Chief executive roles
Nuvectis Pharma Inc.
· Chairman & CEO
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 30, 2026 | Nuvectis Pharma Inc. | Open-market purchase | +12,500 | $20.00 | $250,000 |
| Jan 6, 2026 | Nuvectis Pharma Inc. | Grant or award | +150,000 | — | — |
| Nov 5, 2025 | Nuvectis Pharma Inc. | Open-market purchase | +5,000 | $5.72 | $28,600 |
| Jan 2, 2025 | Nuvectis Pharma Inc. | Grant or award | +250,000 | — | — |
| Dec 24, 2024 | Nuvectis Pharma Inc. | Open-market purchase | +4,500 | $4.65 | $20,925 |
| Nov 15, 2024 | Nuvectis Pharma Inc. | Open-market purchase | +20,000 | $4.92 | $98,400 |
| May 14, 2024 | Nuvectis Pharma Inc. | Open-market purchase | +1,940 | $6.74 | $13,076 |
| May 10, 2024 | Nuvectis Pharma Inc. | Open-market purchase | +2,000 | $6.40 | $12,800 |
| Mar 18, 2024 | Nuvectis Pharma Inc. | Open-market purchase | +5,000 | $10.29 | $51,450 |
| Oct 10, 2023 | Nuvectis Pharma Inc. | Open-market purchase | +640 | $11.08 | $7,091 |
| Oct 9, 2023 | Nuvectis Pharma Inc. | Open-market purchase | +830 | $11.19 | $9,288 |
| Oct 6, 2023 | Nuvectis Pharma Inc. | Open-market purchase | +250 | $11.27 | $2,818 |
| Oct 5, 2023 | Nuvectis Pharma Inc. | Open-market purchase | +1,400 | $11.09 | $15,526 |
| Oct 4, 2023 | Nuvectis Pharma Inc. | Open-market purchase | +1,820 | $10.95 | $19,929 |
| Aug 16, 2023 | Nuvectis Pharma Inc. | Open-market purchase | +115 | $15.15 | $1,742 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.